Skip to main content

Advertisement

SpringerLink
Log in

The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model

  • Research Article
  • Published:
Tumor Biology

Abstract

This study aims to investigate the effect of heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in the malignant pheochromocytoma using a xenograft mouse model. Treatment with 17-AAG induced a marked reduction in the volume and weight of PC12 pheochromocytoma cell tumor xenografts in mice. Furthermore, 17-AAG also significantly inhibited the expression of HSP90 and its client proteins. Our results validated HSP90 as an important target in pheochromocytoma and provided rationale for the testing of HSP90 inhibitors as a promising therapeutic agent in the antitumor therapy of pheochromocytoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Adler JT, Meyer-Rochow GY, Chen H, Benn DE, Robinson BG, Sippel RS, et al. Pheochromocytoma: current approaches and future directions. Oncologist. 2008;13(7):779–93.

    Article  PubMed  Google Scholar 

  2. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2011;96:717–25.

    Article  CAS  PubMed  Google Scholar 

  3. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther. 2006;5(3):522–32.

    Article  CAS  PubMed  Google Scholar 

  4. Pacey S, Gore M, Chao D, et al. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investig New Drugs. 2012;30(1):341–9.

    Article  CAS  Google Scholar 

  5. Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, Larson SM, et al. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol. 2012;69(4):1089–97.

    Article  CAS  PubMed  Google Scholar 

  6. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 2007;6(3):1123–32.

    Article  CAS  PubMed  Google Scholar 

  7. Xu Y, Zhang C, Chen D, Zhao J, Shen Z, Wu Y, et al. Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation. Tumour Biol. 2013;34(6):4065–71.

    Article  PubMed  Google Scholar 

  8. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006;13 Suppl 1:S125–35.

    Article  CAS  PubMed  Google Scholar 

  9. Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537–49.

    Article  CAS  PubMed  Google Scholar 

  10. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761–72.

    Article  CAS  PubMed  Google Scholar 

  11. Gartner EM, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P, et al. A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2012;131:933–7.

    Article  CAS  PubMed  Google Scholar 

  12. Eiseman JL et al. Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol. 2005;55:21–32.

    Article  CAS  PubMed  Google Scholar 

  13. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011;7:818–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther. 2006;5(3):522–32.

    Article  CAS  PubMed  Google Scholar 

  15. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425(6956):407–10.

    Article  CAS  PubMed  Google Scholar 

  16. Giubellino A, Sourbier C, Lee MJ, Scroggins B, Bullova P, Landau M, et al. Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One. 2013;8(2):e56083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Khong T, Spencer A. Targeting HSP90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther. 2011;10:1909–17.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the grants from the National Natural Science Foundation of China (no. 81272936) and Shanghai Municipal Natural Science Foundation (no. 134119a2700).

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Urology, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, 197 Ruijin Er Road, Shanghai, 200025, China

    Yunze Xu, Qi Zhu, Dongning Chen, Zhoujun Shen & Yu Zhu

  2. Department of Urology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    Yunze Xu

  3. Department of Endocrinology, Clinical Center of Shanghai Endocrine and Metabolic Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

    Weiqing Wang & Guang Ning

Authors
  1. Yunze Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qi Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dongning Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhoujun Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weiqing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guang Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu Zhu.

Additional information

Yunze Xu and Qi Zhu share the first authorship of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Y., Zhu, Q., Chen, D. et al. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model. Tumor Biol. 36, 5103–5108 (2015). https://doi.org/10.1007/s13277-015-3162-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3162-3

Keywords

Search

Navigation